MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.33
+0.03
+0.57%
Closed 16:00 06/11 EDT
OPEN
5.34
PREV CLOSE
5.30
HIGH
5.43
LOW
5.20
VOLUME
134.53K
TURNOVER
--
52 WEEK HIGH
14.94
52 WEEK LOW
4.270
MARKET CAP
108.67M
P/E (TTM)
-3.1840
1D
5D
1M
3M
1Y
5Y
BRIEF-Aravive Announces Three New Appointments To Its Board Of Directors
reuters.com · 05/18 11:10
Aravive Announces Three New Appointments to its Board of Directors
Further Strengthens Senior Executive Leadership TeamHOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the appoint...
GlobeNewswire · 05/18 11:00
Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates
Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 16:05
Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancerFirst patient dosed in registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer; on tra...
GlobeNewswire · 05/06 12:00
BRIEF-Aravive Reports Q1 Loss Per Share $0.44
reuters.com · 05/06 11:52
Aravive EPS beats by $0.01, misses on revenue
Aravive (ARAV): Q1 GAAP EPS of -$0.44 beats by $0.01.Revenue of $0.26M misses by $0.09M.Press Release
Seekingalpha · 05/06 11:26
-- Earnings Flash (ARAV) ARAVIVE Reports Q1 Revenue $256,000
MT Newswires · 05/06 07:26
Analysts Are Bullish on Top Healthcare Stocks: Aravive (ARAV), Semler Scientific (SMLR)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAV), Semler Scientific (SMLR) and Aldeyra
SmarterAnalyst · 04/29 11:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARAV. Analyze the recent business situations of Aravive Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARAV stock price target is 22.50 with a high estimate of 26.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 9.36M
% Owned: 45.89%
Shares Outstanding: 20.39M
TypeInstitutionsShares
Increased
18
261.23K
New
15
300.20K
Decreased
16
105.27K
Sold Out
6
86.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Independent Director
Fredric Eshelman
Chairman/Independent Director
fredric Eshelman
President/Chief Executive Officer/Director
Gail McIntyre
Chief Financial Officer
Vinay Shah
Other
Reshma Rangwala
Director
Peter Ho
Director
John Hohneker
Director
Sigurd Kirk
Director
Michael Rogers
Independent Director
Amato Giaccia
Independent Director
Eric Zhang
No Data
  • All
  • Financials
  • Insiders
More
About ARAV
Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.